表紙
市場調査レポート

ウェゲナー肉芽腫症の予測:主要9市場

Wegener's Granulomatosis Forecast in 9 Major Markets 2015-2025

発行 Black Swan Analysis 商品コード 339833
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.50円で換算しております。
Back to Top
ウェゲナー肉芽腫症の予測:主要9市場 Wegener's Granulomatosis Forecast in 9 Major Markets 2015-2025
出版日: 2015年08月01日 ページ情報: 英文 42 Pages
概要

ウェゲナー肉芽腫症は多発血管炎性肉芽腫症として知られる自己免疫疾患で、ANCA関連血管炎による壊死性血管炎が含まれます。

当レポートでは、主要9市場 (米国、フランス、ドイツ、イタリア、スペイン、英国、ブラジル、日本、インド) における多発血管炎性肉芽腫症の現在の患者数 (性別、年齢コホート別) について調査分析し、現在の有病率のほか、危険因子、疾患の診断と予後、主な症状や合併症など、体系的な情報を提供しています。

図表

概要

イントロダクション

病因

危険因子と予防

疾患の診断

変異:地域/民族別

疾患予後と臨床経過

疾患に関連する主な合併症/症候

患者数を定量化する手法

  • 追加データ

ウェゲナー肉芽腫症の有病率トップライン

ウェゲナー肉芽腫症の主な合併症・症候

  • 血管所見
  • ANCA血清状態
  • ウェゲナー肉芽腫症の呼吸器合併症
  • ウェゲナー肉芽腫症のENT症候
  • ウェゲナー肉芽腫症の神経科的症候
  • ウェゲナー肉芽腫症の腎障害

参考文献

付録

目次
Product Code: WEGG0010815

Wegener's Granulomatosis (WG), also known as granulomatous with polyangiitis, is an autoimmune disease, involving necrotizing vasculitis associated with anti-neutrophil cytoplasm antibodies (ANCA). WG primarily involves the upper and lower respiratory tracts and kidneys and originates from an inherited genetic component coupled with an unknown environment stimulus. This report provides the current prevalent population for WG across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity. Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of WG have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for WG include:

  • Renal complications
  • Other autoimmune conditions
  • Respiratory complications
  • Neurological complications
  • Various vascular manifestations
  • Deafness

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global WG's market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of WG and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on WG's prevalent population.
  • Identify sub-populations within WG which require treatment.
  • Gain an understanding of the specific markets that have the largest number of WG patients.

Coverage

US, UK, FR, DE, IT, ES, JP, BR, IN

Table of Contents

List of Tables & Figures

Overview

Introduction

Cause of the Disease

Risk Factors & Prevention

Diagnosis of the Disease

Variation by Geography/Ethnicity

Disease Prognosis & Clinical Course

Key Co-morbid Conditions/Features Associated with the Disease

Methodology for Quantification of Patient Numbers

Top-Line Prevalence for Wegener's Granulomatosis

Main Complications and Presenting Features of Wegener's Granulomatosis

  • Vascular Manifestations
  • ANCA Serology Status
  • Respiratory Complications of Wegner's Granulomatosis
  • ENT Features of Wegner's Granulomatosis
  • Neurological Features of Wegner's Granulomatosis
  • Renal Involvement of Wegner's Granulomatosis

References

Appendix

List of Tables & Figures

  • Prevalence of WG, total (000s)
  • Prevalence of WG, males (000s)
  • Prevalence of WG, females (000s)
  • WG by vascular manifestation, total (000s)
  • ANCA serology status at presentation for WG, total (000s)
  • Respiratory infiltrates & effusions in patients with WG, total (000s)
  • Presence of lung inflammation in patients with WG, total (000s)
  • ENT features at presentation of patients with WG, total (000s)
  • Neurological involvement at presentation of patients with WG, total (000s)
  • Presence of abnormal glomeruli in patients with WG, total (000s)
  • USA Prevalence of WG by 5-yr age cohort, males (000s)
  • USA Prevalence of WG by 5-yr age cohort, females (000s)
  • France Prevalence of WG by 5-yr age cohort, males (000s)
  • France Prevalence of WG by 5-yr age cohort, females (000s)
  • Germany Prevalence of WG by 5-yr age cohort, males (000s)
  • Germany Prevalence of WG by 5-yr age cohort, females (000s)
  • Italy Prevalence of WG by 5-yr age cohort, males (000s)
  • Italy Prevalence of WG by 5-yr age cohort, females (000s)
  • Spain Prevalence of WG by 5-yr age cohort, males (000s)
  • Spain Prevalence of WG by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of WG by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of WG by 5-yr age cohort, females (000s)
  • Brazil Prevalence of WG by 5-yr age cohort, males (000s)
  • Brazil Prevalence of WG by 5-yr age cohort, females (000s)
  • Japan Prevalence of WG by 5-yr age cohort, males (000s)
  • Japan Prevalence of WG by 5-yr age cohort, females (000s)
  • India Prevalence of WG by 5-yr age cohort, males (000s)
  • India Prevalence of WG by 5-yr age cohort, females (000s)
Back to Top